Response to AHCPR on CERTs:
Steven Teutsch, Merck & Co., Inc.
December 4, 1998
I have some suggestions:
- Encourage collaboration with and funding from providers and
industry: with providers to facilitate access to patients and clinical data
which may be important for studies and to demonstrate methods, and with industry
since we have legitimate interests in the appropriate use of
pharmaceutical agents and have expertise. Centers should consider how
large existing databases can be used—this would require identifying the
necessary data elements and data sets which contain them.
- Add research component on adherence/compliance by patients and
providers. This would include research to increase adherence to
guidelines and development of theory and practice of enhancing compliance.
This should be directly linked to demonstrations of effectiveness in
real-world situations. The focus as written is on traditional Food and Drug Administration (FDA)
interests of safety and efficacy, including misuse of pharmaceuticals,
interactions, etc. While appropriate, estimates of underutilization are
equally important.
- Add research component on guideline development for pharmaceutical
agents, implementation and evaluation of programs to increase appropriate
use of pharmaceutical agents.
- Add research component on alternative medications. These are in
wide-spread and increasing use and information is desperately needed about
efficacy, effectiveness, safety and interactions with other medications. FDA has
little jurisdiction over these products, yet their consequences are poorly
understood. Among the issues: are these products used in addition to
pharmaceuticals, do they substitute for them, does their use lead to delay
in seeking effective medication, does their use avoid unnecessary visits
and use of pharmaceuticals?
- Models of organization of the Centers: The Centers for Disease Control (CDC) has models which may be
appropriate, e.g., injury centers, prevention centers, urban research
centers.
Steven Teutsch
Outcomes Research and Management
PO Box 4, WP39-169
Merck & Co., Inc.
West Point, PA 19486-0004
Telephone: (215) 652-2788
Fax: (215) 652-0860
E-mail: steven_teutsch@merck.com
Disclaimer and Copyright
Return to Responses to AHCPR on CERTs
Index of Electronic Reading Room Documents